Physiologically‐based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents-Reference-Cited by-同舟云学术

Physiologically‐based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents

Published:2021-12-14 Issue: Volume: Page:
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst Pharmacol

Author:

Sinha Jaydeep¹²,Karatza Eleni¹,Gonzalez Daniel¹

Affiliation:

1. Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

2. Department of Pediatrics UNC School of Medicine The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12750

Reference42 articles.

1. U.S. Food and Drug AdministrationTRILEPTAL®prescribing information. In: Drugs@FDA.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021014s036lbl.pdf.Accessed August 8 2021.

2. U.S. Food and Drug Administration.KEPPRA®prescribing information. In: Drugs@FDA.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021035s099021505s038lbl.pdf. Accessed August 8 2021.

3. The Limitations of Antiepileptic Drug Monotherapy

4. The metabolism of14C-oxcarbazepine in man

5. Metabolic Characteristics of Oxcarbazepine (®Trileptal) and their Beneficial Implications for Enzyme Induction and Drug Interactions

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically based pharmacokinetic model of brivaracetam to predict the exposure and dose exploration in hepatic impairment and elderly populations;Journal of Pharmaceutical Sciences;2024-09

2. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population;Clinical Pharmacokinetics;2024-05-30

3. Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population;Clinical and Translational Science;2024-04

4. Revisiting the concept of drug‐resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force;Epilepsia;2023-09-07

5. Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations;CPT: Pharmacometrics & Systems Pharmacology;2023-06-02